New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients (Q44491612)

3 December 2017

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients (English)

1 reference

3 December 2017

Marianne Ryberg

1

1 reference

3 December 2017

Dorte Nielsen

2

1 reference

3 December 2017

Giuliana Cortese

3

1 reference

3 December 2017

Gitte Nielsen

4

1 reference

3 December 2017

Torben Skovsgaard

5

1 reference

3 December 2017

Per Kragh Andersen

6

1 reference

3 December 2017

language of work or name

English

0 references

publication date

29 July 2008

1 reference

Journal of the National Cancer Institute

3 December 2017

1 reference

3 December 2017

100

1 reference

3 December 2017

15

1 reference

3 December 2017

1058-1067

1 reference

Risk factors for doxorubicin-induced congestive heart failure

3 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Clinical pharmacokinetics of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Insight into the role of DL-alpha-lipoic acid against cyclophosphamide induced alterations in calcium sensitivity of cardiac myofilaments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Increased glutathione levels and activity of PON1 (phenyl acetate esterase) in the liver of rats after a single dose of cyclophosphamide: a defense mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Radiation-associated cardiovascular disease: manifestations and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Multivariate analysis of prognostic factors in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN206

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN206

1 reference

3 December 2017

1 reference